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Abstract
Robotic prostate biopsy is an emerging technology. Recent development of this tool has allowed the performance of a trans-
perineal prostate biopsy allowing pre-programmed standardized biopsy schemes. Prospective data collection was undertaken 
in 86 consecutive men who underwent robotically assisted transperineal prostate biopsy. All underwent a multi-parametric 
MRI pre-biopsy with centroid targeting followed by systematic template prostate biopsy. For the purposes of this study, our 
definition of clinically significant prostate cancer (csPCa) is any Gleason score > 6. Mean (SD) age, median (IQR) PSA, 
and median (IQR) prostate volume were 64.24 (6.97) years, of 7.79 ng/ml (6.5) and 45.06 cc (28), respectively. Overall, 44 
(51.2%) men were diagnosed with csPCa. csPCa was detected in the targeted biopsies alone in 35 (40.1%) men. The addi-
tion of the 12-zone template biopsy increased the yield of csPCa for another 9 (10.5%) men. Of these 9 men, the majority 
(7) harbored primary pattern 3 disease and only 1 was identified to have high-grade disease. Out of these 9 men, 7 of them 
had the identification of csPCa in the sector, where a target was contained within that zone. Robotic-assisted prostate biopsy 
in our study has demonstrated a high detection of csPCa when combined with limited near-field sampling. Our study sug-
gests the use of more accurate biopsy schemes such as ring-targeting of lesions to mitigate against systematic and random 
mathematical errors. Adoption of this tool and biopsy strategy would potentially avoid the increased morbidity associated 
with whole gland systematic unguided biopsies.
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Introduction
Prostate cancer remains a significant health burden and 
cause of male mortality. Detection of prostate cancer has 
evolved from blind systematic transrectal biopsies to MRI 
lesion directed transperineal biopsy including robotic 
approach such as employed here [1].
There is now level 1b evidence with the results of 
PROMIS demonstrating the clinical benefits of a pre-biopsy 
prostate MRI and using the transperineal (TP) route to pro-
cure prostate tissue for diagnostic purposes [2]. The TP 
route for prostate biopsy also allows the urologist to mitigate 
against the increasing prevalence of fluoroquinolone resist-
ance attributed to the transrectal prostate biopsy [3]. The TP 
prostate biopsy does, however, have a steeper learning curve 
and when coupled with a pre-biopsy MRI requires potential 
additional soft- and hardware to allow MRI-US fusion. One 
such strategy to address and allow greater implementation 
of targeted TP prostate biopsy is the use of a robotic tool.
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Robotic technology has revolutionized surgical treatment 
of prostate cancer with the therapeutic adoption of this tool 
globally [4]. Robotic prostate biopsy and needle localization 
are an emerging technology, which has shown potential to 
positively affect prostate cancer diagnosis and management 
[5]. However, current robotic technology in prostate cancer 
diagnostics almost exclusively uses the transrectal route for 
prostate biopsies [5].
The iSR’obot MonaLisa (Biobot Surgical Ltd, Singa-
pore) is relatively unique in that it allows the performance of 
robotically assisted prostate biopsy with the added benefits 
of allowing it to be performed via the TP route.
Mathematical, systematic, and random errors have been 
measured in fusion biopsy systems and this should also 
be assumed to be present in percutaneous needle delivery 
devices used in robotic technology [6, 7]. Centroid targeting 
involves taking biopsies from the suspected tumor center. 
Ring targeting involves creating a ring around the suspected 
tumor where targets are spaced at equal arc lengths on the 
ring. Targeting strategies such as centroid versus ring target-
ing to mitigate against such errors on the robotic platform 
are yet to be addressed or investigated.
Here, we report on of the largest series of men who under-
went an MRI-USS fusion robotically assisted TP prostate 
biopsy with centroid targeting. Our primary evaluation is 
the detection of clinically significant prostate cancer (csPCa) 




Prospective data collection was undertaken in 86 consecu-
tive men who underwent robotically assisted TP prostate 
biopsy. Patient with a previous diagnosis of a prostate can-
cer was excluded from the study. All men were either a de-
novo prostate biopsy undertaken for an elevated age adjusted 
PSA or abnormal DRE or had a previous negative transrectal 
ultrasound (TRUS) biopsy of their prostate elsewhere and 
were referred to our tertiary center for further evaluation 
and follow-up.
mpMRI
All men underwent a multi-parametric MRI (mpMRI) car-
ried out to minimal standards laid down by British Society 
of Uroradiology and the European Society of Uroradiology. 
That is, coronal or sagittal T2W pelvis, transverse T2W, 
multiple b value ADC, long b value (1500 or 2000 in 1.5 
T or 3 T, respectively), and gadolinium enhanced dynamic 
contrast enhanced T1W axial scans. Images were reviewed 
by a board-certified radiologist (HT) and given a score using 
the PIRADS V2 scoring system 1–5. mpMRI images were 
uploaded into UroFusion (BioBot Surgical Ltd, Singapore) 
software which allowed delineation and contouring the pros-
tate and suspected cancer lesions manually to generate a 3D 
model. Only men harboring PiRADs V2 score 3–5 lesions 
underwent a robotic-assisted prostate biopsy.
Procedure—iSR’obot MonaLisa (Biobot)
Biobot (Biobot surgical, Singapore) is an ultrasound-based 
robot for transperineal prostate biopsy (Figs. 1, 2). It incor-
porates a pre-biopsy MRI with real-time transrectal ultra-
sound images to construct a 3D model of the prostate. All 
MRI targets and prostate boundaries and were defined with 
UroFusion (HT) (BioBot Surgical Ltd, Singapore). The 
iSR’obot™ Mona Lisa robotic transperineal biopsy device 
utilizes a software-controlled robotic arm which we mounted 
onto the operation table via a Micro-Touch™ stabilizer. The 
MonaLisa system was connected to a BK3000 ultrasound 
machine with a transrectal probe which mounted onto 
the robotic arm to provide a TRUS image of the prostate. 
Uploading of the previously generated UroFusion 3-D pros-
tate model and suspected cancer lesions was then performed. 
UroBiopsy (BioBot Surgical Ltd, Singapore) is then used 
to generate the TRUS-based model which allows fusion of 
the mpMRI, and TRUS models. The robot has a gantry that 
utilizes a double dual-cone concept to ensure that the entire 
prostate can be sampled with two 1 mm perineal skin punc-
tures and also defines the penetration depth automatically. 
All procedures were done under general anaesthetic, and at 
Fig. 1  iSR’obot MonaLisa (Biobot Surgical Ltd, Singapore)
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induction, all patients received one dose of intravenous gen-
tamicin 3–5 mg/kg according to local antibiotic guidelines. 
All patients underwent targeted biopsies first using centroid 
targeting of the lesion [7]. This was followed by a 12-zone 
template biopsy using a modified Barzell scheme.
Outcomes
Our primary outcome was the detection of clinically sig-
nificant prostate cancer (csPCa). Our secondary outcome 
included the rate of detection of csPCa for targeted and sys-
tematic sampling. For the purposes of this study, our defini-
tion of csPCa is any Gleason score > 6.
Statistics
Descriptive statistics were used to describe the demo-
graphic data and prostate cancer detection rates. All data 
were entered into an Excel spreadsheet (Microsoft Excel 
Version 15.38) and an imported to STATA (version 13.1) 
for statistical analysis, in accordance with recommendations 
from the Standards of Reporting for MRI-targeted biopsy 
Studies (START) Guidelines [8].
Ethics
Our study was reviewed and approved by our local Audit 
and Service evaluation board (Imperial College Healthcare, 
U.K: registration no. 298).
Results
Demographics
Mean (SD) age, median (IQR) PSA, and median (IQR) pros-
tate volume were 64.24 (6.97) years, of 7.79 ng/ml (6.5) and 
45.06 cc (28), respectively (Table 1). No man had more than 
3 target lesions identified in the pre-biopsy mpMRI (range 
1–3) with a median (IQR) number of targeted biopsy per 
Fig. 2  iSR’obot MonaLisa 
(Biobot Surgical Ltd, Singa-
pore) with BK 3000 transrectal 
ultrasound probe
Table 1  Patient demographics, 
radiological characteristics, and 
number of biopsies taken
Mean ± SD Median IQR
Age (years) 64.24 6.97 63.51 10.63
PSA (ng/ml) 10.00 8.53 7.79 6.5
MRI prostate volume (cc) 51.03 25.24 45.06 28
MRI lesion volume (ml) 1.87 2.42 0.86 1.29
No. of lesions/patient (n) 1.40 0.56 1 1
No. of target biopsies/patient (n) 8.15 3.82 8 4
Target biopsy density (n/ml lesion vol) 9.28 10.36 5.15 10.59
Number of random unguided biopsies/patient 20.20 6.18 20 9
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patient of 8 (4). The median number (IQR) of non-targeted 
biopsy per patient was 20 (9).
Primary outcome
Overall, 44 (51.2%) men were diagnosed with csPCa 
(Table 2). In total, 116 target lesions were identified from 
our cohort of 86 patients. From the 116 MRI lesion identi-
fied, 49 (42.2%) were discovered to have csPCa (Table 3).
Secondary outcomes
csPCa was detected in the targeted biopsies alone in 35 
(40.1%) men. The addition of the 12-zone template biopsy 
increased the yield of significant cancer for 9 (10.5%) men. 
Of these 9 men, the majority (7) harbored primary pattern 
3 disease and only 1 was identified to have high-grade dis-
ease (Table 5). Out of these 9 men, 7 had the identification 
of csPCa in the sector, where a target was contained within 
that zone which suggests that the target was missed narrowly.
With respect to radiological scoring and pathological 
correlation, 16/30 (53.3%) PiRADs v2 score 5 lesions were 
discovered to harbor csPCa (Table 5). For PiRADs v2 scores 
4 and 3 and 2, these figures were 22/55 (40%), 0/22 (0%), 
respectively.
The median maximum cancer core (MCCL) length for 
targeted biopsy was 8 mm versus 7 mm for cancer discov-
ered in non-targeted biopsies which was non-significant.
There was one case of post-biopsy sepsis requiring hos-
pital admission for intravenous antibiotic therapy which was 
the only major complication from this cohort of patients.
Discussion
Our findings provide a timely evaluation of the utilization of 
robotic equipment in the prostate cancer diagnostic pathway 
that utilizes the clinically superior transperineal route. There 
has been an increased adoption of this technology in units 
globally but with minimal reported outcomes [9–11]. The 
detection range of csPCa for all the previous similar stud-
ies is 50.0%, 52.7%, and 61% which is in-keeping with our 
overall detection rate of 51.2%.
The results of PROMIS have now provided level 1 evi-
dence for the application of pre-biopsy mpMRI [2]. This 
is rapidly becoming the standard of care throughout major 
institutions across the U.K and beyond with other centers 
closely following suite due to a national strategy to deliver 
this change [12]. It has been proposed that the introduc-
tion of a robotic tool would potentially shorten the learning 
curve when faced with the challenges of mpMRI-US fusion 
prostate biopsies especially when being performed outside 
the centers of excellence [11].
With respect to the clinical utility of the performance of 
unguided systematic over targeted biopsies, our data dem-
onstrate that an additional 9 men (10.5%) had the exclusive 
presence of csPCa in these non-targeted cores. The median 
maximum MCCL was 6 mm for this cohort which was lower 
than that for targeted biopsies (median MCCL = 8 mm) 
(Tables 4, 5). The treatment modality for this cohort of 
patients was radical prostatectomy [n = 3 (3.5%)], external 
beam radical radiotherapy [n = 3 (3.5%)], and active surveil-
lance (n = 3 (3.5%)).
Our clinical utility of unguided systematic over targeted 
biopsies suggests a significant miss-rate; however, this is 
lower than the 17% reported by Mischinger et al. [11]. How-
ever, the majority of the men in our study had the presence 
of this csPCa within the zone, where the target was con-
tained suggesting only a near-field miss. Within our cohort 
of men, if a targeted biopsy in addition to limited random 
sampling of only the zones, where the targets where present 
would have resulted in only 2 men (2.3%) being missed for 
the presence of csPCa, a more acceptable error rate for this 
Table 2  Detection rate of cancer
Significant cancer = Gleason score > 6
Significant cancer
Overall 44/86 (51.2%)
Target biopsy 35/86 (40.7%)
Exclusively present in random biopsy 9/86 (10.5%)
Table 3  MRI lesion-based detection rate of target biopsies
Significant cancer = Gleason score > 6
PiRADs V2 score Significant cancer n (%) Insignificant 
cancer n (%)
5 16/30 (53.3) 3 + 3 1 1/30 (3.3)
3 + 4 9
4 + 3 5
8–10 2
4 22/55 (40%) 3 + 3 5 5/55 (9.1)
3 + 4 14
4 + 3 4
8–10 4
3 0/22 (0) 3 + 3 2 2/22 (9.1)
3 + 4 0
4 + 3 0
8–10 0
Unclassified 2/9 (22.2) 3 + 3 0 0/9 (0)
3 + 4 1
4 + 3 1
8–10 0
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diagnostic test. The performance of template prostate biop-
sies where a large number of cores are taken in a systematic 
non-targeted manner has been shown to result in a high uri-
nary retention rate and a detrimental impact on genitourinary 
functional outcomes, including deterioration in urinary flow 
and sexual function [13]. The employment of this robotic 
tool where biopsies are undertaken in a targeted manner with 
random samples only in the zone within or around the target 
would avoid excessive unguided prostate sampling. Spacing 
a minimum of three targeted samples around a lesion results 
in a considerably improved yield in simulation experiments 
compared to a centroid approach as utilized in this study 
[7]. The ring-targeting approach accounts and mitigates for 
guidance system, image registration and random errors that 
all accompany MRI-US fusion prostate biopsies [7].
Limiting the number of cores taken will result in effi-
ciency- and cost-savings with the reduction of the number of 
consumables used with subsequent decrease in the burden of 
technical time and workload for our pathology departments 
[14, 15]. The future application and development of such 
a robotic tool could potentially combine biopsy and focal 
ablation into one session when using an accurate real-time 
tissue characterization modality.
This robotic tool does have disadvantages namely time- 
and cost-related factors. The workflow of robotically assisted 
transperineal prostate biopsy is significantly longer due the 
nature of needing to delineate the targets prior to biopsy 
and then longer real-time workflow of the machine in com-
parison with a free-hand transperineal biopsy. There is no 
provision of a sagittal view of the needle trajectory. The 
procedure does not lend itself easily to the local anaesthetic 
approach of a transperineal prostate biopsy due to the longer 
intervention time that is associated with a general anaestheic 
procedure [12]. However, a recent update of the iSR’obot 
MonaLisa (Biobot Surgical Ltd, Singapore) had incorpo-
rated motion compensation within its software which may 
potentially mitigate against this issue.
Our study limitations include the heterogeneous nature 
of our cohort of men which included those with the previ-
ous negative prostate biopsy and men who underwent this 
diagnostic test for the first time. Our study has a small 
size; however, with the exception of study by Mischinger 
et al. [11], our data report on a larger series than found 
in the literature [9, 10]. All men underwent the proce-
dure under general anesthesia. This is not in-keeping with 
global practice, where the majority of prostate biopsies 
are done under local anesthesia within an office setting.
In conclusion, the robotic-assisted prostate biopsy in our 
study has demonstrated a high detection of csPCa when 
combined with only limited near-field sampling. Our study 
suggests that the use of ring-targeting of prostate lesions 
may mitigate against systematic and random mathematical 
errors associated with MRI-US fusion prostate biopsies. 
Adoption of this tool and biopsy strategy would potentially 
avoid the increased morbidity associated with whole gland 
systematic unguided biopsies. Furthermore, it may allow 
users who are relatively new to mpMRI-USS fusion prostate 
biopsies to perform this with added technological security 
whilst on their learning curve for this procedure.
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Table 4  Gleason scores of target prostate biopsies
MCCL = maximum cancer core length in mm
Disease–Gleason 
classification
Target biopsy n (%) Histological charac-
teristics
3 + 3 8/116 (6.9) MCCL med 4.5
MCCL IQR 5.25
3 + 4 24/116 (20.7) MCCL med 7.5
MCCL IQR 6
4 + 3 19/116 (16.4) MCCL med 9.5
MCCL IQR 8
8–10 6/116 (5.2) MCCL med 8
MCCL IQR 5
Table 5  Demographics and pathology of the nine patients discovered 
to have clinically significant disease cancer (Gleason score > 6) exclu-
sively in non-target samples
MCCL maximum cancer core length in mm
Range Med Mean
Age 55.6–73.1 63 63.7
PSA 3.4–24 7.3 8.9
Pros size (cc) 25–68 44 44.8
MCCL 1–8 6 5.3
Gleason score n/9
3 + 4 7/9
4 + 3 1/9
4 + 4 1/9
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